U.S. biotech firm Illumina has enlisted Slaughter and May and Covington & Burling in a legal action against the European Commission over its probe into the group’s $8 billion acquisition of fellow U.S. cancer screening business, GRAIL. 

Illumina, which specialises in genetic sequencing, filed an action with the General Court of the European Union in Brussels on Thursday seeking to annul the Commission’s review, according to a statement by the San Diego-based company.